Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
81.86M | 78.23M | 70.99M | 76.28M | 74.65M | 49.12M | Gross Profit |
74.11M | 71.00M | 62.35M | 67.01M | 65.50M | 41.60M | EBIT |
-15.84M | -16.32M | -22.75M | -55.90M | -66.45M | -87.22M | EBITDA |
239.00K | -1.20M | -15.55M | -57.46M | -65.68M | -85.32M | Net Income Common Stockholders |
-29.89M | -21.54M | -35.48M | -76.39M | -81.65M | -98.33M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
73.68M | 84.48M | 73.68M | 94.24M | 110.50M | 144.16M | Total Assets |
107.73M | 128.78M | 107.73M | 144.22M | 166.07M | 188.81M | Total Debt |
131.75M | 128.96M | 131.75M | 131.17M | 130.70M | 125.20M | Net Debt |
58.06M | 44.48M | 58.06M | 36.93M | 20.20M | -18.95M | Total Liabilities |
194.34M | 169.15M | 194.34M | 200.84M | 187.84M | 182.03M | Stockholders Equity |
-86.61M | -40.36M | -86.61M | -56.62M | -21.77M | 6.79M |
Cash Flow | Free Cash Flow | ||||
-22.70M | -44.75M | -20.86M | -67.71M | -77.10M | -86.75M | Operating Cash Flow |
-22.86M | -44.89M | -20.53M | -67.65M | -76.94M | -86.21M | Investing Cash Flow |
-50.00K | -72.00K | -328.00K | -63.00K | -62.00K | -546.00K | Financing Cash Flow |
55.55M | 55.55M | 300.00K | 51.44M | 43.32M | 83.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
50 Neutral | $97.22M | ― | 75.79% | ― | 10.58% | 34.44% | |
35 Underperform | $83.54M | ― | 48.74% | ― | ― | -1.60% | |
33 Underperform | $146.71M | 41.82 | 4.14% | ― | ― | 33.97% | |
33 Underperform | $27.97M | ― | -125.43% | ― | ― | 2.98% |
Optinose, a company involved in the pharmaceutical industry, has undergone significant changes following a merger agreement. On May 21, 2025, Optinose was acquired by Paratek Pharmaceuticals, resulting in the termination of Optinose’s obligations under its Note Purchase Agreement and the delisting of its common stock from Nasdaq. The merger, valued at approximately $330 million, includes contingent value rights for Optinose shareholders based on future sales milestones of their product XHANCE. This acquisition expands Paratek’s portfolio, which now includes Optinose’s XHANCE alongside Paratek’s antibiotic NUZYRA, positioning Paratek as a multi-product specialty therapeutics company.
The most recent analyst rating on (OPTN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Optinose stock, see the OPTN Stock Forecast page.
On May 16, 2025, OptiNose, Inc. held a special meeting of stockholders where key proposals were voted on. The company, involved in a merger with Paratek Pharmaceuticals, Inc., had 10,127,381 shares eligible to vote, with a quorum of 8,406,605 shares represented. The stockholders approved the Merger Agreement Proposal with Paratek, receiving a 77.96% affirmative vote. Additionally, the Advisory Compensation Proposal was approved with an 81.65% affirmative vote. The Adjournment Proposal was deemed unnecessary due to sufficient votes for the merger.
The most recent analyst rating on (OPTN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Optinose stock, see the OPTN Stock Forecast page.